Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

References

• Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56–67
   PubMed Web of Science ®Google Scholar
• Alzheimer's Disease International. World Alzheimer Report 2009, London 2009
   Google Scholar
• Mahlberg R, Gutzmann H. Diagnostik von Demenzerkrankungen. Deutsches Ärzteblatt 2005;102:A2032–2039
   Google Scholar
• Forsyth E, Ritzline PD. An overview of the etiology, diagnosis, and treatment of Alzheimer disease. Phys Ther 1998;78:1325–1331
   PubMedGoogle Scholar
• BMG. Available at: http://www.bmg.bund.de/cln_110/nn_1168278/SharedDocs/Standardartikel/DE/AZ/D/Glossarbegriff-Demenz.html. Accessed 5 December 2008
   Google Scholar
• Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia. Alzheimers Dement 2009;6:98–103
   Google Scholar
• Jönsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics 2009;27:391–403
   PubMed Web of Science ®Google Scholar
• Cummings JL. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis 2004;1:60–69
   PubMedGoogle Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261–2268
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269–2276
   PubMed Web of Science ®Google Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Cholinesterasehemmer bei Demenz, Abschlussbericht, Auftrag A05-19A, 07.02.2007, www.iqwig.de
   Google Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Aktualisierungsrecherche zum Bericht A09-19A (Cholinesterasehemmer bei Demenz). Rapid Report, Auftrag A09-03, 12.10.2009, www.iqwig.de
   Google Scholar
• Sano M, Wilcock GK, van Baelen B, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18:942–950
   PubMedGoogle Scholar
• Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009;24:479–488
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001;57:964–971
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003;18:740–747
   PubMed Web of Science ®Google Scholar
• Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003;25:1806–1825
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, et al. Assessment of Health Economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002;14:84–89
   PubMed Web of Science ®Google Scholar
• Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002;20:629–637
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001;57:972–978
   PubMed Web of Science ®Google Scholar
• Gemeinsamer Bundesausschuss (G‐BA). Arzneimittelrichtlinie – Anlage III: Übersicht über Versorgungseinschränkungen und –ausschlüsse in der Arzneimittelversorgung durch die Arzneimittelrichtlinie und aufgrund anderer Vorschriften (§ 34 Abs. 1 Satz 6 und Abs. 3 SGB V), 19.02.2010
   Google Scholar
• Gemeinsamer Bundesausschuss (G‐BA). Ergänzungsauftrag zur Nutzenbewertung von Cholinesterasehemmern zur Behandlung der Alzheimer Demenz. 18.12.2009, http://www.g-ba.de/downloads/39-261-1075/2009-12-17-IQWiG-Cholinesterasehemmern.pdf
   Google Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Kosten und Nutzen. Version 1.0, 12.10.2009, www.iqwig.de
   Google Scholar
• Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323–332
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000;321:1445–1449
   PubMed Web of Science ®Google Scholar
• Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2002;2:6
   PubMed Web of Science ®Google Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Ginkgohaltige Präparate bei Alzheimer Demenz. Auftrag A05-19B, Abschlussbericht. 29.09.2008, www.iqwig.de
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. MidCity Mace, London, November 2006. Available at: www.nice.org.uk. Accessed 9 December 2008
   Google Scholar
• Gesundheitsberichterstattung des Bundes. Available at: http://www.gbe-bund.de/. Accessed 15 November 2009
   Google Scholar
• Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–396
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:852–857
   PubMed Web of Science ®Google Scholar
• Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–595
   PubMed Web of Science ®Google Scholar
• Brodaty H, Corey-Bloom J, Potocnik FCV, et al. Comparison of the efficacy and tolerability of galantamine prolonged- and immediate-release formulations in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120–132
   PubMed Web of Science ®Google Scholar
• Aronson SM, Baelen B van, Kershaw P. Greater benefits for patients receiving sustained vs. interrupted treatment with galantamine. The 9th International Conference on Alzheimer's Disease and Related Diseases, Philadelphia, USA, July 17–22, 2004
   Google Scholar
• Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimer's Type. Curr Alzheimer Res 2005;2:541–551
   PubMedGoogle Scholar
• German Life Table 2006. Available at: http://www.mortality.org/hmd/DEUTNP/STATS/mltper_1x1.txt. Accessed 15 October 2009
   Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 2005;229:43–49
   PubMed Web of Science ®Google Scholar
• IMS Health, IMS Disease Analyzer, Jan 2008 – Dec 2008 JC data on file. IMS Health Deutschland. http://www.imshealth.de/sixcms/detail.php/307, letzter Zugriff 20.01.2010
   Google Scholar
• Lauer-Taxe Online, www.lauer-fischer.de. Accessed 20 October 2009
   Google Scholar
• Schwabe U, Paffrath D (Hrsg.). Arzneiverordnungsreport 2008. Berlin, Heidelberg: Springer-Verlag, 2008:305–317
   Google Scholar
• Kassenärztliche Bundesvereinigung.Einheitlicher Bewertungsmaßstab, Stand 01.01.2009, http://www.kbv.de/ebm2010/ebmgesamt.htm. Accessed 4 November 2009
   Google Scholar
• Bundesministerium für Gesundheit. www.bmgs.de. Accessed 27 October 2009
   Google Scholar
• Kulp W, Graf v.d. Schulenburg J-M. Pharmakoökonomische Aspekte der Behandlung von Demenz-Patienten. Pharmazie unserer Zeit 2002;31:410–416
   Google Scholar
• Gräßel E, Donath C, Lauterberg J, et al. Demenzkranke und Pflegestufen: Wirken sich Krankheitssymptome auf die Einstufung aus? Gesundheitswesen 2008;70:129–136
   Google Scholar
• Feldman HH, Van Baelen B, Kavanagh SM, et al. Cognition, function, and caregiving time patterns in patients with mild‐to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29–36
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Ewers M, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2007;257:330–336
   PubMed Web of Science ®Google Scholar
• Tun SM, Murman DL, Long HL, et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007;15:314–327
   Google Scholar
• Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 2010;28:411–427
   PubMed Web of Science ®Google Scholar
• Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009;24:479–488
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; CD003120
   Google Scholar
• Weyerer S. Altersdemenz. Robert-Koch-Institut (RKI) (ed.) Gesundheitsberichtserstattung des Bundes – Heft 28. 15.11.2005, www.rki.de
   Google Scholar